Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine
about
When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?Leflunomide: a drug with a potential beyond rheumatologyUsing estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis.Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study.Advances in the treatment of rheumatoid arthritis: old versus new therapies.Leflunomide for treating rheumatoid arthritis.Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis.Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis.Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology.Current and investigational treatment of psoriatic arthritis.Sulphasalazine inhibits human antigen-specific immune responses in vivo.Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis.Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.Leflunomide in rheumatoid arthritis: recommendations through a process of consensus.Leflunomide: long-term clinical experience and new uses.Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesHypertension in rheumatoid arthritis.Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis.Therapeutic options for rheumatoid arthritis.Leflunomide-induced DRESS syndrome with renal involvement and vasculitis.Safety evaluation of leflunomide in rheumatoid arthritis.Current immunotherapy in rheumatoid arthritis.Neutropenia in the Elderly: A Rheumatology Perspective.Follow up studies in rheumatoid arthritis.Leflunomide in the treatment of psoriasis: results of a phase II open trial.Leflunomide in the treatment of rheumatoid arthritis.Guidelines for the drug treatment of rheumatoid arthritis.The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study.Drug-induced arterial hypertension - a frequently ignored cause of secondary hypertension: a review.[Therapeutic strategies in rheumatoid arthritis].Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model.Serum IFN-γ levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis.
P2860
Q24673434-7D0AAEB8-47FD-4812-97D3-2B835A9B3DFAQ28294236-C16FD544-73A1-4604-9A4E-D6EA17367C79Q30739084-3CC20FF7-1DF2-431A-AE32-760CD2BD33ADQ33188521-3B4D582B-02CB-4EEE-9334-97E12230D533Q34706876-87815D20-6320-4179-A8A8-C65D2CA418C3Q35048594-E10D6AAC-0026-4ED5-A769-AF3BBC1E9CEEQ35194346-46DD0CAF-5B53-4ECB-AC55-D611F01B55F8Q35555116-89E60CE0-B208-414F-B772-50B2E9390085Q35605474-27B54F32-855F-479F-9926-A85FDAC2DC6BQ35680654-6E83AB3F-E94A-4A21-8703-AE3765F8AD1BQ35760185-F299715A-9386-4560-9E25-A05973DA1316Q35826806-08CAF80A-E033-49E1-9F23-A227637B8E38Q35953478-27E4688E-D3C5-40F7-BA56-D2F905994966Q36013041-BB402FA5-2DA9-4F2C-A36D-3F944BA251BBQ36150789-D82480A6-2ECC-4811-8CA1-47DD5C7FDCB0Q36408155-85F6801E-BB85-4FFD-9ACD-E6A89047CDD9Q36724093-DA8BA24C-BFEA-4FD7-9F00-E8D33D845B45Q37158219-B5780C31-D7A9-4A80-9DB3-CFF141CF7DD6Q37358239-580C1F92-2CFB-485F-A792-406965DA71C3Q37552947-08E02B1F-5F09-4182-8EA1-2AA99C4F560BQ38070124-EBAE765E-9944-4646-9209-56111277911FQ38106213-1E619CE5-F8D3-47E1-A348-427115E36585Q38133655-68F9EBE9-C8C4-4666-B541-76DC012CA620Q38893238-40BC43C0-BD52-4960-AFDD-2AE7979DFEDDQ41963511-B490E19B-39D6-4569-A74B-C3D1D773E494Q42627416-0383B6B9-1597-45D4-855A-B27A0B069686Q43061691-17B0D118-A443-416F-8640-2B8C269D7C3CQ43675571-1EA3B20C-DBFD-4EF8-A740-D98562B28D6DQ44470594-78054F2B-0011-4FEF-BF48-D4C292D90D85Q47757118-5162C224-2EFF-4020-B6F9-B2D4FF235285Q52895477-F2146802-6E43-4943-A879-4F1D7A984E4DQ53799480-3DB452BF-1991-424A-B094-B322BE7FF21DQ55472570-E32B5A10-A637-4A38-A82E-06B566345867
P2860
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Treatment of active rheumatoid ...... led trial versus sulfasalazine
@ast
Treatment of active rheumatoid ...... led trial versus sulfasalazine
@en
Treatment of active rheumatoid ...... led trial versus sulfasalazine
@nl
type
label
Treatment of active rheumatoid ...... led trial versus sulfasalazine
@ast
Treatment of active rheumatoid ...... led trial versus sulfasalazine
@en
Treatment of active rheumatoid ...... led trial versus sulfasalazine
@nl
prefLabel
Treatment of active rheumatoid ...... led trial versus sulfasalazine
@ast
Treatment of active rheumatoid ...... led trial versus sulfasalazine
@en
Treatment of active rheumatoid ...... led trial versus sulfasalazine
@nl
P2093
P2860
P356
P1476
Treatment of active rheumatoid ...... led trial versus sulfasalazine
@en
P2093
I Loew-Friedrich
J R Kalden
J S Smolen
L B van de Putte
M Schattenkirchner
P2860
P304
P356
10.1136/ARD.60.10.913
P407
P577
2001-10-01T00:00:00Z